Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response

Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with hepatitis C virus (HCV) genotype 2. As RBV cannot be used in certain situations, we examined whether PEG-IFN-alfa-2a monotherapy for 24 weeks or less would be suf...

Full description

Saved in:
Bibliographic Details
Published inBMC research notes Vol. 4; no. 1; p. 316
Main Authors Etoh, Reiko, Imazeki, Fumio, Kurihara, Tomoko, Fukai, Kenichi, Fujiwara, Keiichi, Arai, Makoto, Kanda, Tatsuo, Mikata, Rintaro, Yonemitsu, Yutaka, Yokosuka, Osamu
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 31.08.2011
BioMed Central
BMC
Subjects
Care and treatment
Drug therapy, Combination
Genotype & phenotype
Health aspects
Hepatitis
Hepatitis C
Interferon alfa-2a
Statistical analysis
Japan
Online AccessGet full text

Cover

Abstract Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with hepatitis C virus (HCV) genotype 2. As RBV cannot be used in certain situations, we examined whether PEG-IFN-alfa-2a monotherapy for 24 weeks or less would be sufficient to obtain a sustained virological response (SVR) in patients infected with HCV genotype 2. Forty-nine consecutive patients with HCV genotype 2 received PEG-IFN-alfa-2a (180 μg/week) subcutaneously without oral RBV for 8-64 weeks. HCV RNA level was determined by COBAS AMPLICOR HCV Test, v2.0. HCV RNA was equal to or less than 100 KIU/mL (defined as low viral load) in 15 of 49 patients, and the remaining 34 had HCV RNA above 100 KIU/mL (defined as high viral load). All 15 patients with low viral load achieved rapid virological response (RVR; HCV RNA negative at week 4), and also achieved SVR with an average treatment duration of 17.1 weeks. The 34 patients with high viral load were treated for 33.7 weeks on average, and 19 of them (55.9%) achieved RVR. The SVR rates of these patients were significantly higher in those with RVR than without RVR (16/19 vs. 6/15 p = 0.0074). PEG-IFN-alfa-2a monotherapy for 24 weeks or less might be sufficient to treat selected patients with HCV genotype 2, especially those with low viral load and becoming negative for HCV RNA by week 4 of treatment.
AbstractList Background Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with hepatitis C virus (HCV) genotype 2. As RBV cannot be used in certain situations, we examined whether PEG-IFN-alfa-2a monotherapy for 24 weeks or less would be sufficient to obtain a sustained virological response (SVR) in patients infected with HCV genotype 2. Methods Forty-nine consecutive patients with HCV genotype 2 received PEG-IFN-alfa-2a (180 [mu]g/week) subcutaneously without oral RBV for 8-64 weeks. HCV RNA level was determined by COBAS AMPLICOR HCV Test, v2.0. Results HCV RNA was equal to or less than 100 KIU/mL (defined as low viral load) in 15 of 49 patients, and the remaining 34 had HCV RNA above 100 KIU/mL (defined as high viral load). All 15 patients with low viral load achieved rapid virological response (RVR; HCV RNA negative at week 4), and also achieved SVR with an average treatment duration of 17.1 weeks. The 34 patients with high viral load were treated for 33.7 weeks on average, and 19 of them (55.9%) achieved RVR. The SVR rates of these patients were significantly higher in those with RVR than without RVR (16/19 vs. 6/15 p = 0.0074). Conclusion PEG-IFN-alfa-2a monotherapy for 24 weeks or less might be sufficient to treat selected patients with HCV genotype 2, especially those with low viral load and becoming negative for HCV RNA by week 4 of treatment.
Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with hepatitis C virus (HCV) genotype 2. As RBV cannot be used in certain situations, we examined whether PEG-IFN-alfa-2a monotherapy for 24 weeks or less would be sufficient to obtain a sustained virological response (SVR) in patients infected with HCV genotype 2. Forty-nine consecutive patients with HCV genotype 2 received PEG-IFN-alfa-2a (180 [mu]g/week) subcutaneously without oral RBV for 8-64 weeks. HCV RNA level was determined by COBAS AMPLICOR HCV Test, v2.0. HCV RNA was equal to or less than 100 KIU/mL (defined as low viral load) in 15 of 49 patients, and the remaining 34 had HCV RNA above 100 KIU/mL (defined as high viral load). All 15 patients with low viral load achieved rapid virological response (RVR; HCV RNA negative at week 4), and also achieved SVR with an average treatment duration of 17.1 weeks. The 34 patients with high viral load were treated for 33.7 weeks on average, and 19 of them (55.9%) achieved RVR. The SVR rates of these patients were significantly higher in those with RVR than without RVR (16/19 vs. 6/15 p = 0.0074). PEG-IFN-alfa-2a monotherapy for 24 weeks or less might be sufficient to treat selected patients with HCV genotype 2, especially those with low viral load and becoming negative for HCV RNA by week 4 of treatment.
Abstract Background Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with hepatitis C virus (HCV) genotype 2. As RBV cannot be used in certain situations, we examined whether PEG-IFN-alfa-2a monotherapy for 24 weeks or less would be sufficient to obtain a sustained virological response (SVR) in patients infected with HCV genotype 2. Methods Forty-nine consecutive patients with HCV genotype 2 received PEG-IFN-alfa-2a (180 μg/week) subcutaneously without oral RBV for 8-64 weeks. HCV RNA level was determined by COBAS AMPLICOR HCV Test, v2.0. Results HCV RNA was equal to or less than 100 KIU/mL (defined as low viral load) in 15 of 49 patients, and the remaining 34 had HCV RNA above 100 KIU/mL (defined as high viral load). All 15 patients with low viral load achieved rapid virological response (RVR; HCV RNA negative at week 4), and also achieved SVR with an average treatment duration of 17.1 weeks. The 34 patients with high viral load were treated for 33.7 weeks on average, and 19 of them (55.9%) achieved RVR. The SVR rates of these patients were significantly higher in those with RVR than without RVR (16/19 vs. 6/15 p = 0.0074). Conclusion PEG-IFN-alfa-2a monotherapy for 24 weeks or less might be sufficient to treat selected patients with HCV genotype 2, especially those with low viral load and becoming negative for HCV RNA by week 4 of treatment.
BACKGROUND: Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with hepatitis C virus (HCV) genotype 2. As RBV cannot be used in certain situations, we examined whether PEG-IFN-alfa-2a monotherapy for 24 weeks or less would be sufficient to obtain a sustained virological response (SVR) in patients infected with HCV genotype 2. METHODS: Forty-nine consecutive patients with HCV genotype 2 received PEG-IFN-alfa-2a (180 μg/week) subcutaneously without oral RBV for 8-64 weeks. HCV RNA level was determined by COBAS AMPLICOR HCV Test, v2.0. RESULTS: HCV RNA was equal to or less than 100 KIU/mL (defined as low viral load) in 15 of 49 patients, and the remaining 34 had HCV RNA above 100 KIU/mL (defined as high viral load). All 15 patients with low viral load achieved rapid virological response (RVR; HCV RNA negative at week 4), and also achieved SVR with an average treatment duration of 17.1 weeks. The 34 patients with high viral load were treated for 33.7 weeks on average, and 19 of them (55.9%) achieved RVR. The SVR rates of these patients were significantly higher in those with RVR than without RVR (16/19 vs. 6/15 p = 0.0074). CONCLUSION: PEG-IFN-alfa-2a monotherapy for 24 weeks or less might be sufficient to treat selected patients with HCV genotype 2, especially those with low viral load and becoming negative for HCV RNA by week 4 of treatment.
Abstract Background Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with hepatitis C virus (HCV) genotype 2. As RBV cannot be used in certain situations, we examined whether PEG-IFN-alfa-2a monotherapy for 24 weeks or less would be sufficient to obtain a sustained virological response (SVR) in patients infected with HCV genotype 2. Methods Forty-nine consecutive patients with HCV genotype 2 received PEG-IFN-alfa-2a (180 μg/week) subcutaneously without oral RBV for 8-64 weeks. HCV RNA level was determined by COBAS AMPLICOR HCV Test, v2.0. Results HCV RNA was equal to or less than 100 KIU/mL (defined as low viral load) in 15 of 49 patients, and the remaining 34 had HCV RNA above 100 KIU/mL (defined as high viral load). All 15 patients with low viral load achieved rapid virological response (RVR; HCV RNA negative at week 4), and also achieved SVR with an average treatment duration of 17.1 weeks. The 34 patients with high viral load were treated for 33.7 weeks on average, and 19 of them (55.9%) achieved RVR. The SVR rates of these patients were significantly higher in those with RVR than without RVR (16/19 vs. 6/15 p = 0.0074). Conclusion PEG-IFN-alfa-2a monotherapy for 24 weeks or less might be sufficient to treat selected patients with HCV genotype 2, especially those with low viral load and becoming negative for HCV RNA by week 4 of treatment.
BACKGROUNDPegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with hepatitis C virus (HCV) genotype 2. As RBV cannot be used in certain situations, we examined whether PEG-IFN-alfa-2a monotherapy for 24 weeks or less would be sufficient to obtain a sustained virological response (SVR) in patients infected with HCV genotype 2. METHODSForty-nine consecutive patients with HCV genotype 2 received PEG-IFN-alfa-2a (180 μg/week) subcutaneously without oral RBV for 8-64 weeks. HCV RNA level was determined by COBAS AMPLICOR HCV Test, v2.0. RESULTSHCV RNA was equal to or less than 100 KIU/mL (defined as low viral load) in 15 of 49 patients, and the remaining 34 had HCV RNA above 100 KIU/mL (defined as high viral load). All 15 patients with low viral load achieved rapid virological response (RVR; HCV RNA negative at week 4), and also achieved SVR with an average treatment duration of 17.1 weeks. The 34 patients with high viral load were treated for 33.7 weeks on average, and 19 of them (55.9%) achieved RVR. The SVR rates of these patients were significantly higher in those with RVR than without RVR (16/19 vs. 6/15 p = 0.0074). CONCLUSIONPEG-IFN-alfa-2a monotherapy for 24 weeks or less might be sufficient to treat selected patients with HCV genotype 2, especially those with low viral load and becoming negative for HCV RNA by week 4 of treatment.
Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with hepatitis C virus (HCV) genotype 2. As RBV cannot be used in certain situations, we examined whether PEG-IFN-alfa-2a monotherapy for 24 weeks or less would be sufficient to obtain a sustained virological response (SVR) in patients infected with HCV genotype 2. Forty-nine consecutive patients with HCV genotype 2 received PEG-IFN-alfa-2a (180 μg/week) subcutaneously without oral RBV for 8-64 weeks. HCV RNA level was determined by COBAS AMPLICOR HCV Test, v2.0. HCV RNA was equal to or less than 100 KIU/mL (defined as low viral load) in 15 of 49 patients, and the remaining 34 had HCV RNA above 100 KIU/mL (defined as high viral load). All 15 patients with low viral load achieved rapid virological response (RVR; HCV RNA negative at week 4), and also achieved SVR with an average treatment duration of 17.1 weeks. The 34 patients with high viral load were treated for 33.7 weeks on average, and 19 of them (55.9%) achieved RVR. The SVR rates of these patients were significantly higher in those with RVR than without RVR (16/19 vs. 6/15 p = 0.0074). PEG-IFN-alfa-2a monotherapy for 24 weeks or less might be sufficient to treat selected patients with HCV genotype 2, especially those with low viral load and becoming negative for HCV RNA by week 4 of treatment.
ArticleNumber 316
Audience Academic
Author Arai, Makoto
Yonemitsu, Yutaka
Fukai, Kenichi
Kurihara, Tomoko
Imazeki, Fumio
Mikata, Rintaro
Kanda, Tatsuo
Etoh, Reiko
Yokosuka, Osamu
Fujiwara, Keiichi
AuthorAffiliation 1 Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
AuthorAffiliation_xml – name: 1 Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
Author_xml – sequence: 1
  givenname: Reiko
  surname: Etoh
  fullname: Etoh, Reiko
  email: kandat-cib@umin.ac.jp
  organization: Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan. kandat-cib@umin.ac.jp
– sequence: 2
  givenname: Fumio
  surname: Imazeki
  fullname: Imazeki, Fumio
– sequence: 3
  givenname: Tomoko
  surname: Kurihara
  fullname: Kurihara, Tomoko
– sequence: 4
  givenname: Kenichi
  surname: Fukai
  fullname: Fukai, Kenichi
– sequence: 5
  givenname: Keiichi
  surname: Fujiwara
  fullname: Fujiwara, Keiichi
– sequence: 6
  givenname: Makoto
  surname: Arai
  fullname: Arai, Makoto
– sequence: 7
  givenname: Tatsuo
  surname: Kanda
  fullname: Kanda, Tatsuo
– sequence: 8
  givenname: Rintaro
  surname: Mikata
  fullname: Mikata, Rintaro
– sequence: 9
  givenname: Yutaka
  surname: Yonemitsu
  fullname: Yonemitsu, Yutaka
– sequence: 10
  givenname: Osamu
  surname: Yokosuka
  fullname: Yokosuka, Osamu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/21884572$$D View this record in MEDLINE/PubMed
BookMark eNp1kk1v1DAQhiNURD_gzA1FcEAc0vo7yQWprICuVKkcoFfLsSdZrxI72NnCXvjtOGxZdVGRpdiaeeeJ_c6cZkfOO8iylxidY1yJC1xyUSCOUMEKisWT7GQfOXpwPs5OY1wjJHBV4WfZMUk74yU5yX59gW7bqwlMbt0EoYXgXaH6VhVE5YN3flpBUOM2pfNRTRbcFNO5BT3X_LDTKr9a3OYdJOV2hJzkyiXWMPowKach922e6q3J72zwve-sVn0eII7eRXiePW1VH-HF_X6Wffv08eviqri--bxcXF4XDRdIFLpukMZMqIYwTgxihjBMGJSmrI0CJGooK40wr1olGkSMKI1QpCGk5pyamp5lyx3XeLWWY7CDClvplZV_Aj50UoXJ6h5kxUuqNKG0og1DRNRclLSpW1GxVjW6TKz3O9a4aQYwOjkSVH8APcw4u5Kdv5OUpNvXOAE-7ACN9f8BHGa0H-TcSzn3UjKZOp0gb-9vEfz3DcRJDjZq6HvlwG-irGpa4pqy-e2v_1Gu_Sa4ZLesEWGUETrj3uxEnUoepP769Gc9I-UlESXnKH2S6vwRVVoGBqvTaLY2xQ8K3h0UJM0EP6dObWKUy5vbQ-3FTquDjzFAu3cEIzlP-yMevHrYib3-73jT32Sa-qw
CitedBy_id crossref_primary_10_1016_j_ijid_2015_12_002
crossref_primary_10_3390_biology6020030
crossref_primary_10_1111_hepr_12024
Cites_doi 10.1016/S1089-3261(05)70210-5
10.1016/j.jhep.2006.12.017
10.1056/NEJM200012073432301
10.1007/s12072-010-9193-3
10.1056/NEJMoa042608
10.1002/hep.23976
10.1080/00365540902998271
10.1136/gut.2007.133884
10.1006/viro.1993.1058
10.1002/jmv.22038
10.1053/j.gastro.2010.05.079
10.1002/hep.1840220406
10.3109/00365521.2011.574731
10.1016/j.jhep.2010.07.041
10.1053/j.gastro.2008.10.049
10.1002/hep.22253
10.1002/hep.1840190605
10.1016/0140-6736(93)90635-T
10.1016/j.jhep.2010.07.032
10.1056/NEJM200012073432302
10.1002/hep.510260706
10.1056/NEJMoa066403
10.1111/j.1365-2893.2010.01409.x
10.1093/infdis/jir193
10.1128/jcm.31.4.882-886.1993
10.1099/0022-1317-74-4-661
10.1002/hep.1840190629
10.1002/hep.510240405
10.1159/000080876
ContentType Journal Article
Copyright COPYRIGHT 2011 BioMed Central Ltd.
2011 Imazeki et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright ©2011 Imazeki et al; licensee BioMed Central Ltd. 2011 Imazeki et al; licensee BioMed Central Ltd.
Copyright_xml – notice: COPYRIGHT 2011 BioMed Central Ltd.
– notice: 2011 Imazeki et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
– notice: Copyright ©2011 Imazeki et al; licensee BioMed Central Ltd. 2011 Imazeki et al; licensee BioMed Central Ltd.
DBID NPM
AAYXX
CITATION
IOV
3V.
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/1756-0500-4-316
DatabaseName PubMed
CrossRef
Gale In Context: Opposing Viewpoints
ProQuest Central (Corporate)
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
AUTh Library subscriptions: ProQuest Central
ProQuest Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection (Proquest) (PQ_SDU_P3)
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
Medical Database
Biological Science Database
Publicly Available Content (ProQuest)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList



CrossRef
MEDLINE - Academic
PubMed
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1756-0500
EndPage 316
ExternalDocumentID oai_doaj_org_article_8573ac23383b402695673b9f684fabc7
oai_biomedcentral_com_1756_0500_4_316
2504577451
A267550675
10_1186_1756_0500_4_316
21884572
Genre Journal Article
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GroupedDBID ---
-A0
0R~
23N
2VQ
2WC
3V.
4.4
53G
5GY
5VS
6J9
7X7
88E
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEAQA
AFKRA
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C1A
C24
C6C
CCPQU
CS3
DIK
E3Z
EBLON
EBS
EJD
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IEA
IHR
INH
INR
IOV
IPNFZ
ITC
KQ8
LK8
M1P
M48
M7P
MK0
M~E
NPM
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RIG
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
~8M
AAYXX
CITATION
AFGXO
ABVAZ
AFNRJ
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-b5606-c9b0c146ab2452d04d24124e7d79dae069e78c0158fa6b02d67d6a2b229553d93
IEDL.DBID RPM
ISSN 1756-0500
IngestDate Thu Jul 04 21:11:03 EDT 2024
Tue Sep 17 21:22:08 EDT 2024
Wed May 22 07:16:41 EDT 2024
Fri Aug 16 20:46:34 EDT 2024
Fri Sep 13 09:00:42 EDT 2024
Thu Feb 22 23:52:05 EST 2024
Fri Feb 02 04:03:00 EST 2024
Thu Aug 01 20:27:19 EDT 2024
Thu Sep 12 17:49:25 EDT 2024
Sat Sep 28 07:59:02 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b5606-c9b0c146ab2452d04d24124e7d79dae069e78c0158fa6b02d67d6a2b229553d93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224591/
PMID 21884572
PQID 902434236
PQPubID 55247
ParticipantIDs doaj_primary_oai_doaj_org_article_8573ac23383b402695673b9f684fabc7
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3224591
biomedcentral_primary_oai_biomedcentral_com_1756_0500_4_316
proquest_miscellaneous_893719349
proquest_journals_902434236
gale_infotracmisc_A267550675
gale_infotracacademiconefile_A267550675
gale_incontextgauss_IOV_A267550675
crossref_primary_10_1186_1756_0500_4_316
pubmed_primary_21884572
PublicationCentury 2000
PublicationDate 20110831
PublicationDateYYYYMMDD 2011-08-31
PublicationDate_xml – month: 8
  year: 2011
  text: 20110831
  day: 31
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC research notes
PublicationTitleAlternate BMC Res Notes
PublicationYear 2011
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References 20001276 - Scand J Infect Dis. 2009;41(6-7):389-402
21063477 - Hepatol Int. 2010 Aug 19;4(3):548-61
21606533 - J Infect Dis. 2011 Jun 15;203(12 ):1748-52
19084016 - Gastroenterology. 2009 Feb;136(2):496-504.e3
7678473 - Virology. 1993 Feb;192(2):430-7
7557850 - Hepatology. 1995 Oct;22(4 Pt 1):1050-6
10349693 - Semin Liver Dis. 1999;19 Suppl 1:57-65
17881538 - Gut. 2008 Apr;57(4):525-30
8855176 - Hepatology. 1996 Oct;24(4):778-89
8385694 - J Gen Virol. 1993 Apr;74 ( Pt 4):661-8
18454508 - Hepatology. 2008 Jun;47(6):1837-45
17625124 - N Engl J Med. 2007 Jul 12;357(2):124-34
21112657 - J Hepatol. 2011 Mar;54(3):415-21
11106715 - N Engl J Med. 2000 Dec 7;343 (23 ):1666-72
15564744 - Intervirology. 2004;47(6):328-34
8385151 - J Clin Microbiol. 1993 Apr;31(4):882-6
21604145 - Dig Dis Sci. 2011 Nov;56(11):3335-42
8188183 - Hepatology. 1994 Jun;19(6):1513-20
21129130 - J Viral Hepat. 2011 Jul;18(7):e292-7
21112660 - J Hepatol. 2011 Mar;54(3):408-14
17328985 - J Hepatol. 2007 Jun;46(6):1009-17
21254157 - Hepatology. 2011 Jan;53(1):7-13
21360545 - J Med Virol. 2011 May;83(5):871-8
9305661 - Hepatology. 1997 Sep;26(3 Suppl 1):34S-38S
11685796 - Clin Liver Dis. 2001 Nov;5(4):1073-90
20621700 - Gastroenterology. 2010 Sep;139(3):821-7, 827.e1
11106716 - N Engl J Med. 2000 Dec 7;343 (23 ):1673-80
7514558 - Hepatology. 1994 Jun;19(6):1347-53
8099380 - Lancet. 1993 Jun 12;341(8859):1501-4
15972867 - N Engl J Med. 2005 Jun 23;352(25):2609-17
21529139 - Scand J Gastroenterol. 2011 Jul;46(7-8):955-61
ML Yu (1066_CR20) 2011; 53
JY Lau (1066_CR23) 1993; 341
M Lindh (1066_CR28) 2011; 203
N Sakamoto (1066_CR27) 2011; 83
M Martinot-Peignoux (1066_CR22) 1995; 22
S Nakamoto (1066_CR29) 2011; 46
S Zeuzem (1066_CR11) 2000; 343
EJ Heathcote (1066_CR10) 2000; 343
T Kanda (1066_CR15) 2011; 18
ML Shiffman (1066_CR5) 2007; 357
M Lagging (1066_CR31) 2009; 41
C Sarrazin (1066_CR25) 2011; 54
CH Liu (1066_CR9) 2008; 57
A Mangia (1066_CR24) 2010; 139
T Kanda (1066_CR30) 2011
JG McHutchison (1066_CR12) 1999; 19
T Poynard (1066_CR21) 1996; 24
CJ Liu (1066_CR4) 2009; 136
A Mangia (1066_CR6) 2005; 352
VJ Desmet (1066_CR19) 1994; 19
M Angelico (1066_CR8) 2007; 46
KKY Young (1066_CR14) 1993; 31
T Kanda (1066_CR3) 2010; 4
T Tanaka (1066_CR17) 1994; 19
T Kawaoka (1066_CR26) 2011; 54
A Ahmed (1066_CR2) 2001; 5
P Simmonds (1066_CR18) 1993; 74
M Lagging (1066_CR7) 2008; 47
O Yokosuka (1066_CR13) 2004; 47
AM Di Bisceglie (1066_CR1) 1997; 3
K Tsukiyama-Kohara (1066_CR16) 1993; 192
References_xml – volume: 5
  start-page: 1073
  year: 2001
  ident: 1066_CR2
  publication-title: Clin Liver Dis
  doi: 10.1016/S1089-3261(05)70210-5
  contributor:
    fullname: A Ahmed
– volume: 46
  start-page: 1009
  year: 2007
  ident: 1066_CR8
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2006.12.017
  contributor:
    fullname: M Angelico
– volume: 19
  start-page: 57
  issue: suppl 1
  year: 1999
  ident: 1066_CR12
  publication-title: Semin Liver Dis
  contributor:
    fullname: JG McHutchison
– volume: 343
  start-page: 1666
  year: 2000
  ident: 1066_CR11
  publication-title: N Engl J Med
  doi: 10.1056/NEJM200012073432301
  contributor:
    fullname: S Zeuzem
– volume: 4
  start-page: 548
  year: 2010
  ident: 1066_CR3
  publication-title: Hepatol Int
  doi: 10.1007/s12072-010-9193-3
  contributor:
    fullname: T Kanda
– volume: 352
  start-page: 2609
  year: 2005
  ident: 1066_CR6
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa042608
  contributor:
    fullname: A Mangia
– volume: 53
  start-page: 7
  year: 2011
  ident: 1066_CR20
  publication-title: Hepatology
  doi: 10.1002/hep.23976
  contributor:
    fullname: ML Yu
– volume: 41
  start-page: 389
  year: 2009
  ident: 1066_CR31
  publication-title: Scand J Infect Dis
  doi: 10.1080/00365540902998271
  contributor:
    fullname: M Lagging
– volume: 57
  start-page: 525
  year: 2008
  ident: 1066_CR9
  publication-title: Gut
  doi: 10.1136/gut.2007.133884
  contributor:
    fullname: CH Liu
– volume: 192
  start-page: 430
  year: 1993
  ident: 1066_CR16
  publication-title: Virology
  doi: 10.1006/viro.1993.1058
  contributor:
    fullname: K Tsukiyama-Kohara
– volume: 83
  start-page: 871
  year: 2011
  ident: 1066_CR27
  publication-title: J Med Virol
  doi: 10.1002/jmv.22038
  contributor:
    fullname: N Sakamoto
– volume: 139
  start-page: 821
  year: 2010
  ident: 1066_CR24
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2010.05.079
  contributor:
    fullname: A Mangia
– volume: 22
  start-page: 1050
  year: 1995
  ident: 1066_CR22
  publication-title: Hepatology
  doi: 10.1002/hep.1840220406
  contributor:
    fullname: M Martinot-Peignoux
– volume: 46
  start-page: 955
  year: 2011
  ident: 1066_CR29
  publication-title: Scand J Gastroenterol
  doi: 10.3109/00365521.2011.574731
  contributor:
    fullname: S Nakamoto
– volume: 54
  start-page: 415
  year: 2011
  ident: 1066_CR25
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2010.07.041
  contributor:
    fullname: C Sarrazin
– volume: 136
  start-page: 496
  year: 2009
  ident: 1066_CR4
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2008.10.049
  contributor:
    fullname: CJ Liu
– volume: 47
  start-page: 1837
  year: 2008
  ident: 1066_CR7
  publication-title: Hepatology
  doi: 10.1002/hep.22253
  contributor:
    fullname: M Lagging
– volume: 19
  start-page: 1347
  year: 1994
  ident: 1066_CR17
  publication-title: Hepatology
  doi: 10.1002/hep.1840190605
  contributor:
    fullname: T Tanaka
– volume: 341
  start-page: 1501
  year: 1993
  ident: 1066_CR23
  publication-title: Lancet
  doi: 10.1016/0140-6736(93)90635-T
  contributor:
    fullname: JY Lau
– volume: 54
  start-page: 408
  year: 2011
  ident: 1066_CR26
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2010.07.032
  contributor:
    fullname: T Kawaoka
– volume: 343
  start-page: 1673
  year: 2000
  ident: 1066_CR10
  publication-title: N Engl J Med
  doi: 10.1056/NEJM200012073432302
  contributor:
    fullname: EJ Heathcote
– volume: 3
  start-page: 34S
  issue: Suppl 1
  year: 1997
  ident: 1066_CR1
  publication-title: Hepatology
  doi: 10.1002/hep.510260706
  contributor:
    fullname: AM Di Bisceglie
– volume: 357
  start-page: 124
  year: 2007
  ident: 1066_CR5
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa066403
  contributor:
    fullname: ML Shiffman
– volume: 18
  start-page: e292
  year: 2011
  ident: 1066_CR15
  publication-title: J Viral Hepat
  doi: 10.1111/j.1365-2893.2010.01409.x
  contributor:
    fullname: T Kanda
– volume: 203
  start-page: 1748
  year: 2011
  ident: 1066_CR28
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jir193
  contributor:
    fullname: M Lindh
– volume-title: Dig Dis Sci
  year: 2011
  ident: 1066_CR30
  contributor:
    fullname: T Kanda
– volume: 31
  start-page: 882
  year: 1993
  ident: 1066_CR14
  publication-title: J Clin Microbiol
  doi: 10.1128/jcm.31.4.882-886.1993
  contributor:
    fullname: KKY Young
– volume: 74
  start-page: 661
  year: 1993
  ident: 1066_CR18
  publication-title: J Gen Virol
  doi: 10.1099/0022-1317-74-4-661
  contributor:
    fullname: P Simmonds
– volume: 19
  start-page: 1513
  year: 1994
  ident: 1066_CR19
  publication-title: Hepatology
  doi: 10.1002/hep.1840190629
  contributor:
    fullname: VJ Desmet
– volume: 24
  start-page: 778
  year: 1996
  ident: 1066_CR21
  publication-title: Hepatology
  doi: 10.1002/hep.510240405
  contributor:
    fullname: T Poynard
– volume: 47
  start-page: 328
  year: 2004
  ident: 1066_CR13
  publication-title: Intervirology
  doi: 10.1159/000080876
  contributor:
    fullname: O Yokosuka
SSID ssj0061881
Score 1.9684818
Snippet Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with hepatitis C virus...
Abstract Background Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with...
Background Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with hepatitis...
Abstract Background: Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with...
BACKGROUNDPegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with hepatitis C...
BACKGROUND: Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with hepatitis...
Abstract Background Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard treatment protocol for patients with...
SourceID doaj
pubmedcentral
biomedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 316
SubjectTerms Care and treatment
Drug therapy, Combination
Genotype & phenotype
Health aspects
Hepatitis
Hepatitis C
Interferon alfa-2a
Statistical analysis
SummonAdditionalLinks – databaseName: BioMedCentral
  dbid: RBZ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagCIlLxZvQgiyEBJeIxIntWJzaimpB4nGgVcXF8ittpSWpNt3DXvjtzCTebd1y45oZW4lnPJ5xZr4h5K1grHGidTkvEFRbsIBJACG3riidtVx5h4XCX7-J2VH95YSfXIFF3_iDXzbiA5xvEPPyoshrMBjiLrnHEOMcA_P9X2ujK8pm7Ee6YY4oPv-Y4EZl-zw5kEbc_tvW-drxlKZOXjuLDh-S7ehE0r1J6o_IndA9JventpKrJ-TPj3C6moMT6SmiQSzasOi73MxbkzNDQe9i1dUKyDQCqw50SsuCMXg1S2cHxxTxW_GKljJqOpjr9-irg5bQvqUw_txTrJKL1pMupnTb8JQcHX76eTDLY5-F3IK_I3KnbOHAYhqLv2F9UXuGPamD9FJ5EwqhgmxAdrxpjbAF80J6YZjFTuC88qp6Rra6vgsvCLVlq0ylfHAGQq-ytaAIHHykwJg0hVUZ-Zgsvr6YMDU0olynFNhwGkWnUXS61iC6jLxfi2ozcAxiGnGbdR9Fmcw_PgDV0nFT6obLyjiGUbqFOFpArCgrq1rR1K2xTmbkDSqCRpyMDhNxTs1yGPTn78d6j0GkhfrNM_IuMrU9vLgzsa4BFgShtRLO3YQTNrJLyDtrfdPRkAxaIWIkuLzwQXRDxYGYG9eFfjlo9DjBDa9hcZ9Pyrn5avDfmppLlhGZqG2yLCmlOz8bQcbB0NdclS__S2A75MHVHfwu2bpcLMMrcOIu7etx-_4F7x1C9A
  priority: 500
  providerName: BioMedCentral
– databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuiDehBVkICS5RE2_sxOJUKqoFiceBVr1ZfpZKS4I23cNe-ts7E3uXNT1w4Rrb0Wbm83jGO_MNIW8EY50VwZa8QlJtwTwmAfjS2Kq2xnDpLBYKf_kq5qfN53N-vtPqC3PCIj1wFNxhx9uZtgwjKQOxjgB_vp0ZGUTXBG1srCOv-SaYijZY1N3UnhTORoiXeVUlUp-6E4fbZ2UDBkj8Vei-yM6nicb_trHeOa3yTMqdo-nkAbmffEp6FL_lIbnj-0fkbuwyuX5Mrr_7i_UCfEpHkRxiGfxy6Eu9CLpkmgIMUxHWGoZp4lkdaczSgjV4U0vnx2cU6VzxxpYyqnt416_JdQfQ0CFQWH_pKBbNJWNKlzH71j8hpycffxzPy9R2oTTg_ojSSlNZMKDa4L-yrmocwxbVvnWtdNpXQvq2A1XyLmhhKuZE64RmBhuD85mTs6dkrx96_5xQUwepZ9J5qyESq4MBXHBwmTxjra6MLMj7TPjqd6TYUEh6nY_A_lOoOoWqU40C1RXk3UZV24VTTNOJ21M_oCqz908PAGoqQU39C2oFeY1AUEib0WNezoVejaP69O1MHTEIvBDuvCBv06QwwA-3OpU5gECQaSubeZDNhH1ts-H9Dd5UsiujkkggCR4wfBDdjuJCTJXr_bAaFTqg4JU3INxnEZzbrwZ3rmt4ywrSZrDNxJKP9Jc_J85xsPsNl_WL_yHHfXLvz838Adm7Wq78S3DtrsyraRffAJjsScs
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: AUTh Library subscriptions: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9QwDI_GJiReEN90GyhCSPBSXZtr0kY8oG3aOJAYE2LT3qJ89Zh0tNv17uFe-Nux29yxMInXOqna2HFsx_6ZkLeCscqK2qY8Q1BtwTwmAfjU2Cy3xnDpLBYKfz0Vk_PiyyW_3CKf1rUwmFa51om9onatxRj5SCJ0Hpz9YqQNBgHsYvTx-ibF9lF4zRp6adwjOywv8L525_D49Oz7WimLvKrygOyTV2IEhyY40jzL0gK0kPin2n0WHVI9lv9djX3ryIrTKW-dTyePyMNgWNKDQRIeky3fPCH3h1aTq6fk95mfrmZgWDqKCBHz2s_bJtWzWqdMU_inUIm1AjINYKsdHVK1YA6Ga-nk6IIipiuGbSmjuoF3_ertd5Ac2tYU5l85ipVzQaPS-ZCC65-R85PjH0eTNPReSA3YQCK10mQWtKg2eDXrssIx7FPtS1dKp30mpC8r4Cevai1MxpwondDMYHdwPnZy_JxsN23jXxJq8lrqsXTeanDH8tqAcHCwmzxjpc6MTMiHaPHV9YCzoRD5OqaAQChknULWqUIB6xLyfs2qzcTesanE3aGHyMro_f2Ddj5VYaOqipdjbRl67gZ8awH-Yzk2shZVUWtjy4S8QUFQiJ3RYHLOVC-7Tn3-dqEOGHhfKPM8Ie_CoLpFWdWh1gEWBOG2opH70UjY3DYi763lTQXl0qnNVkgI3VBxIubLNb5ddgqtUDDNC1jcF4Nwbv4abLqq4CVLSBmJbbQsMaW5-tkDj4PyL7jMd__7UXvkwd-4-z7ZXsyX_hUYbgvzOmzKP_U5RQ0
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELagCIkL4t20BVkICS6BrGM7sRBCpaJakAoc2Ko3y68slZaEZrsSe-G3M5Nk05r2wDVjW8k87Bln5htCXkjGSicrl4oMQbUlC5gEEFLrsomzVijvsFD46IuczvjnE3Fy0Q5oYODy2tAO-0nN2sXr32fr92Dw7zqDL-UbOAEhKhZZlnLYUuRNcovxnKO6H_Hxl4KclF3H0nHwgPNzzQL_1L4voiOrQ_a_un9fOsDi5MpLp9XhPXJ3cDPpfq8X98mNUD8gt_vGk-uH5M-3MF8vwM30FPEi2iq0TZ2aRWVSZiho5lCXtQYyHaBXl7RP3II5eHlLpwfHFBFe8RKXMmpqWOtnx0jQI9pUFOafeop1dMP-Sts-ITc8IrPDj98PpunQiSG14BHJ1CmbOdhTjcUftT7jnmHX6lD4QnkTMqlCUYJ0RVkZaTPmZeGlYRZ7hYvcq_wx2aqbOmwTaieVMrnywRkIziaVBVUR4EUFxgqTWZWQtxHz9a8edUMjDnZMAZPUKDqNotNcg-gS8mojqnFiF-aU8urQDyjKaP3uQdPO9WC2uhRFbhzDON5CpC0hmixyqypZ8spYVyTkOSqCRiSNGlN15ma1XOpPX4_1PoNYDC1AJOTlMKhq4MWdGSofgCEIvhWN3ItGgqm7iLy70Te9sRStEFMSnGL4IDpScSJmz9WhWS01-qTgqHNg7pNeOcevBg-v5KJgCSkitY3YElPq0x8dDDkcBVyoyc7_sGCX3Lm4jN8jW-ftKjwFb-7cPuus9C_ECEaX
  priority: 102
  providerName: Scholars Portal
Title Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response
URI https://www.ncbi.nlm.nih.gov/pubmed/21884572
https://www.proquest.com/docview/902434236/abstract/
https://search.proquest.com/docview/893719349
http://dx.doi.org/10.1186/1756-0500-4-316
https://pubmed.ncbi.nlm.nih.gov/PMC3224591
https://doaj.org/article/8573ac23383b402695673b9f684fabc7
Volume 4
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swEBZtx2AvY7-btQtiDLYXN7ZsyTJ7SkJLFkgXurWUvQhJlrNAYpekecjL_vbd2U5W0be9OBBJxtZ9d7qT7z4R8kkwJq0obMBDJNUWzGESgAuMDSNrDM9yi4XCk0sxuk7Gt_z2gPBdLUydtG_N_KxcLM_K-e86t_JuaXu7PLHedDIEECY8i3qH5DCN412I3phfEUkZtRw-kRQ9WB4hZOZhGCRgb0RN_itlwpES2CtxX3grU03g_9hMP1in_BzKB4vSxQvyvPUmab956pfkwJWvyNPmfMnta_Jn6mbbBXiTOUVaiFXhVlUZ6EWhA6YpALAtv9pCM20ZVte0yc-CMbhHS0fDG4pErrhXSxnVJdxrWTvtABdaFRTGz3OK5XKtGaWrJu_WvSHXF-c_h6OgPXAhMOD4iMBmJrRgOrXB77F5mOQMD6d2aZ5muXahyFwqQYhcFlqYkOUizYVmBo8E53GexW_JUVmV7phQExWZjrPcWQ0xWFQYQAQHZ8kxlurQZB3y1Zt8ddeQayiku_ZbQPMUSlGhFFWiQIod8mUnqv3AOpqR4nHXAYrSu3_9R7WaqRZUSvI01pZhuG4goBYQNKaxyQohk0Ibm3bIRwSCQsKMEjNyZnqzXqtv329Un0HIhUDnHfK57VRU8OBWtwUOMCHIseX1PPV6gkZbr_lkhzfVWpS1ypA6EnxfeCG6b8WBmCRXumqzVuh6gj-ewOS-a8C5f-sd5jsk9WDrTYvfAspXs423yvb-v0eekGf_NuJPydH9auM-gCd3b7qgv7dplzzp98c_xvA7OL-cXnXrfRG4ThIJ16vBr26t4X8BrU1QPg
link.rule.ids 108,230,315,733,786,790,870,891,2115,2236,12083,21416,24346,24965,27957,27958,31754,31755,33779,33780,43345,43840,53827,53829,76169,76170
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKwQXxJvQAhZCgkvUxImdWBxQW7XaQrtUqK16s_zKUmlJyqZ72Au_nZnEuzRU4pqxo8Qznoc98w0h7wVjpRWVjXmCoNqCeUwC8LGxSWqN4dJZLBQ-nojxWf7lgl-E3Jw2pFWudGKnqF1j8Yx8WyJ0Hth-8fnqV4xNo_ByNXTQuEs28gwilRHZ2N2fnHxfqWKRlmUa8HzSUmyDqYTwmSdJnIPuEf_UuM8GpqlD8L-tp28YqmES5Q2rdPCIPAzuJN3p-f-Y3PH1E3KvbzC5fEp-n_jpcgbupKOICzGv_LypYz2rdMw0hX8K9VdLINMAsdrSPkEL5uAhLR3vnVNEcsXDWsqoruFdPzuvHeSFNhWF-ZeOYr1c0KN03ife-mfk7GD_dG8ch44LsQHPR8RWmsSC7tQGL2RdkjuG3al94QrptE-E9EUJXORlpYVJmBOFE5oZ7AnOMyez52RUN7V_SahJK6kz6bzVEISllQGR4OAtecYKnRgZkU-DxVdXPbqGQrzrIQXEQCHrFLJO5QpYF5GPK1atJ3bhTCluD91FVg7e3z1o5lMVtqcqeZFpyzBeNxBRC4gai8zISpR5pY0tIvIOBUEhYkaNKTlTvWhbdfjtXO0wiLlQ0nlEPoRBVQMfbnWocIAFQZCtwcitwUjY0nZA3lzJmwoqpVXrDRARuqbiRMySq32zaBX6nuCQ57C4L3rhXP81eHJlzgsWkWIgtoNlGVLqyx8d3Dio_JzL9NV_P-otuT8-PT5SR4eTr5vkwd-T9y0yup4v_Gtw3a7Nm7BB_wAro0RA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgEYgL70fZBSyEBJe0iZs4sTgthVUX2KUHdrXai-VXSkWbVH0cyoHfzkwepWZve-3YUe18Hs8433wm5C1nLDM8N0ESoqg2Zw5JAC7QJoyM1omwBguFT0758Cz-cpFc7Fz1VZH2jZ50i-msW0x-VtzK-cz0Wp5Yb3QyABDGiYh6c5v3bpJbsGaZaBP12gnzKMuiRsknyngPNklInJMwDGLwOrySAM6yOEFhYK_QfertT5WM_1VnvbNb-UzKna3p6D65bAdVM1J-ddcr3TW__9N7vNaoH5B7TcBKD-smD8kNVzwit-srLDePyZ-RG2-mELBaisoTi9wtyiJQ01wFTFHAeFPhtQEzbURcl7SmgEEfPAamw8E5Ra1YPA6mjKoCnjWr8gJAJC1zCv0nlmJFXuOp6aKm9ron5Ozo84_BMGjudAg0xFY8MEKHBryz0vjJ14axZXj_tUttKqxyIRcuzQAnSZYrrkNmeWq5YhpvHU_6VvSfkr2iLNxzQnWUC9UX1hkFaV6UawBdAvGYYyxVoRYd8sF7s3Je63dIVNT2LbC4JUJEIkRkLAEiHfK-xcG2Y5UwZfxq04-IE-_51Q_lYiybNyizJO0rw_BEQEPOziEvTfta5DyLc6VN2iFvEGUSNTkKJP2M1Xq5lMffz-Uhg6wO11LSIe-aRnkJf9yopoYCJgRlvLyWB15LcBrGM--3YJaN01pKgeqUEF7DgOjWih2Rh1e4cr2UGN1CyB_D5D6rkb8ddbugOiT11oQ3Lb4FkF4JmjfIfnHtnq_JndGnI_nt-PTrPrn779j_gOytFmv3EuLGlX5VeYi_53FtxQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pegylated+interferon-alfa-2a+monotherapy+in+patients+infected+with+HCV+genotype+2+and+importance+of+rapid+virological+response&rft.jtitle=BMC+research+notes&rft.au=Etoh%2C+Reiko&rft.au=Imazeki%2C+Fumio&rft.au=Kurihara%2C+Tomoko&rft.au=Fukai%2C+Kenichi&rft.date=2011-08-31&rft.pub=BioMed+Central+Ltd&rft.issn=1756-0500&rft.eissn=1756-0500&rft.volume=4&rft.spage=316&rft_id=info:doi/10.1186%2F1756-0500-4-316&rft.externalDBID=IOV&rft.externalDocID=A267550675
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-0500&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-0500&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-0500&client=summon